{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T04:17:49Z","timestamp":1744431469837,"version":"3.40.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1053\/j.jvca.2025.01.031","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:17:48Z","timestamp":1737677868000},"page":"1348-1351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Con: The Patient With Recent Intake of Direct Oral Anticoagulants\u2014Problems Are Not Solved With the Approval of Reversal Agents"],"prefix":"10.1053","volume":"39","author":[{"given":"Marc","family":"Maegele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2458-9342","authenticated-orcid":false,"given":"Maria","family":"Ntalouka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.jvca.2025.01.031_bib0001","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"Gomez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.jvca.2025.01.031_bib0002","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.jvca.2025.01.031_bib0003","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13054-023-04327-7","article-title":"The European guideline on the management of major bleeding and coagulopathy following trauma: Sixth edition","volume":"27","author":"Rossiant","year":"2023","journal-title":"Crit Care"},{"key":"10.1053\/j.jvca.2025.01.031_bib0004","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/EJA.0000000000001968","article-title":"Clinical guideline on reversal of direct oral anticoagulants in patients with life threatening bleeding","volume":"41","author":"Grottke","year":"2024","journal-title":"Eur J Anaesthesiol"},{"key":"10.1053\/j.jvca.2025.01.031_bib0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"When and how to use antidotes for the reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.jvca.2025.01.031_bib0006","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal: Full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.jvca.2025.01.031_bib0007","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Eng J Med"},{"key":"10.1053\/j.jvca.2025.01.031_bib0008","first-page":"505","article-title":"Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab","volume":"121","author":"Hegemann","year":"2018","journal-title":"Br J Anaesth Case Reports"},{"key":"10.1053\/j.jvca.2025.01.031_bib0009","doi-asserted-by":"crossref","first-page":"ezad100","DOI":"10.1093\/ejcts\/ezad100","article-title":"Andexanet alfa in acute aortic syndrome: First UK experience","volume":"63","author":"Al-Attar","year":"2023","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1053\/j.jvca.2025.01.031_bib0010","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.jvca.2020.10.042","article-title":"Successful antithrombin administration in andexanet alfa-associated heparin resistance","volume":"35","author":"Apostel","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.01.031_bib0011","doi-asserted-by":"crossref","first-page":"e01636","DOI":"10.1213\/XAA.0000000000001636","article-title":"Heparin insensitivity and thrombotic risk associated with sequential uses of prothrombin complex concentrate and andexanet alfa for apixaban reversal during acute type A aortic dissection repair: A case report","volume":"16","author":"Brenner","year":"2022","journal-title":"A A Pract"},{"key":"10.1053\/j.jvca.2025.01.031_bib0012","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1213\/XAA.0000000000001052","article-title":"Andexanet alfa for urgent reversal of apixaban before aortic surgery requiring cardiopulmonary bypass: a case report","volume":"13","author":"Flaherty","year":"2019","journal-title":"A A Pract"},{"key":"10.1053\/j.jvca.2025.01.031_bib0013","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40981-023-00619-7","article-title":"Successful use of an antithrombin for heparin resistance with andexanet alfa","volume":"9","author":"Honda","year":"2023","journal-title":"JA Clin Rep"},{"key":"10.1053\/j.jvca.2025.01.031_bib0014","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1053\/j.jvca.2020.08.017","article-title":"Intraoperative off-label reversal of apixaban by andexanet alfa while on VA-ECMO immediately after emergent surgery for acute type A aortic dissection","volume":"35","author":"Kainz","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.01.031_bib0015","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat Med"},{"key":"10.1053\/j.jvca.2025.01.031_bib0016","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/phar.2306","article-title":"Intraoperative unfractionated heparin unresponsiveness during endovascular repair of a ruptured abdominal aortic aneurysm following administration of andexanet alfa for the reversal of rivaroxaban","volume":"39","author":"Eche","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1053\/j.jvca.2025.01.031_bib0017","first-page":"01153","article-title":"Nonvitamin K oral anticoagulant in cardiac surgery: Continuing education continues to evolve","volume":"S0022-5223","author":"Beller","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1053\/j.jvca.2025.01.031_bib0018","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1053\/j.jvca.2021.03.011","article-title":"STS\/SCA\/AmSECT\/SABM update to the clinical practice guidelines on patient blood management","volume":"35","author":"Tibi","year":"2021","journal-title":"J Cardiothorac Vasc Aneth"},{"key":"10.1053\/j.jvca.2025.01.031_bib0019","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1053\/j.jvca.2021.09.032","article-title":"Clinical practice guidelines for anesthesiologists on patient blood management in cardiac surgery","volume":"35","author":"Huang","year":"2021","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.01.031_bib0020","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1053\/j.jvca.2023.02.039","article-title":"Safety of andexanet alfa use in cardiac surgery","volume":"37","author":"Huang","year":"2023","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1053\/j.jvca.2025.01.031_bib0021","unstructured":"European Medicines Agency. Direct healthcare professional communication Ondexxya (andexanet alfa): Avoid use of andexanet prior to heparinization. 2020. (Accessed October 31, 2023).https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/ondexxya-andexanet-alfa-avoid-use-andexanet-prior-heparinization."},{"key":"10.1053\/j.jvca.2025.01.031_bib0022","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025000886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077025000886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T19:38:54Z","timestamp":1744400334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077025000886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1053077025000886"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2025.01.031","relation":{},"ISSN":["1053-0770"],"issn-type":[{"type":"print","value":"1053-0770"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Con: The Patient With Recent Intake of Direct Oral Anticoagulants\u2014Problems Are Not Solved With the Approval of Reversal Agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2025.01.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2025.02.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}